Grufity logo
Grufity logo
VCYT

VCYT - Veracyte Inc Stock Price, Fair Value and News

$56.98-2.32 (-3.91%)
Market Closed as of 10 Jul 2026, 04:00 pm ET

53/100

VCYT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

53/100

VCYT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

VCYT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VCYT Price Action

Last 7 days

-0.2%

Last 30 days

18.3%

Last 90 days

83.3%

Trailing 12 Months

107.1%

VCYT RSI Chart

VCYT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VCYT Valuation

Market Cap

4.5B

Price/Earnings (Trailing)

51.66

Price/Sales (Trailing)

8.39

EV/EBITDA

38.17

Price/Free Cashflow

29.27

VCYT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

VCYT Fundamentals

VCYT Revenue

Revenue (TTM)

541.7M

Rev. Growth (Yr)

21.49%

Rev. Growth (Qtr)

-1.11%

VCYT Earnings

Earnings (TTM)

88.0M

Earnings Growth (Yr)

307.36%

Earnings Growth (Qtr)

-30.24%

VCYT Profitability

Operating Margin

93.34%

EBT Margin

16.75%

Return on Equity

6.55%

Return on Assets

6.13%

Free Cashflow Yield

3.42%

VCYT Investor Care

Shares Dilution (1Y)

2.26%

Diluted EPS (TTM)

1.08

VCYT Alerts

  • 5 major insider sales recently.
Revenue & Growth

How Veracyte Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026541.7M---
2025463.4M479.1M495.1M517.1M
2024375.5M399.6M425.3M445.8M
2023311.2M328.6M343.1M361.1M
2022250.6M268.4M283.6M296.5M
2021123.1M157.5M186.7M219.5M
2020122.0M112.5M112.7M117.5M
2019101.5M108.9M116.4M120.4M
201875.6M79.9M85.9M92.0M
201768.0M71.7M70.6M72.0M
201651.8M54.6M60.9M65.1M
201541.9M45.2M47.7M49.5M
201425.0M28.6M32.8M38.2M
201314.5M17.1M19.5M21.9M
20124.9M7.1M9.4M11.6M
2011---2.6M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Veracyte Inc

VCYT
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEveracyte.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES787

Veracyte Inc Frequently Asked Questions

VCYT is the stock ticker symbol of Veracyte Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jul 10 2026, market cap of Veracyte Inc is 4.55 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jul 10 2026, VCYT's PE ratio (Price to Earnings) is 51.66 and Price to Sales (PS) ratio is 8.39. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VCYT PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Veracyte Inc has provided 0.27 (multiply by 100 for percentage) rate of return.